Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

This Government Contract opportunity from Department Of Health And Human Services was posted on December 2, 2024. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

ADVANCING CLINICAL TRIALS READINESS (ACTR)

Closed
ARPA-H-SN-25-121Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541715
New
Federal
Common Autonomous Multi-Domain Launcher (CAML)-Lite Prototype Effort
Solicitation # W50RAJ27CAML_LITE
The Common Autonomous Multi-Domain Launcher (CAML)-Lite Prototype Effort is a competitive procurement conducted under 10 U.S.C. section 4022 Other Transaction Authority to develop a mobile, optionally manned, autonomous launcher for cross-domain offensive and defensive fires. The program is structured in two phases, beginning with Phase 1, which requires a prototype demonstration at Talisman Sabre 2027 in August 2027. This initial phase includes a priced option for the acquisition of additional prototype units, New Equipment Training, and Contractor Logistics Support. Phase 2 focuses on prototype maturation and integration into a common CAML architecture. The government seeks solutions that utilize a Modular Open Systems Approach to ensure interchangeable modules and autonomous munition resupply with minimal human intervention. The procurement process begins with the submission of a Solutions Brief, with a deadline of October 26, 2026. The government will evaluate these briefs based on technical soundness, credibility in addressing objectives, and the feasibility of the maturation path to select the most meritorious respondents for a subsequent Request for Prototype Proposal. Award for Phase 1 is expected by December 18, 2026. Selected performers must assume full responsibility for international logistics and compliance for transporting systems to Australia. Funding for the demonstration will be provided at initial award, though performer investment is required and may positively influence selection. Final acceptance of the effort is contingent upon successful performance verification, cybersecurity Authority to Operate, and government approval of the Technical Data Package.
W6DV Peo M & S Redstone

POSTED

about 14 hours ago

DEADLINE

in 2 days
NAICS: 541715
New
Federal
Protein Palace Proposers Day
Solicitation # DARPA-SN-27-01
The Defense Advanced Research Projects Agency (DARPA) is initiating the Protein Palace program to develop a universal, tunable protein purification platform. This initiative aims to replace the traditional lock-and-key paradigm with a system capable of purifying multiple proteins from a single system by leveraging unique physicochemical characteristics to improve specificity, generalizability, and scalability in biomanufacturing. The program is structured into two distinct phases: a 24-month Phase 1 focused on proving feasibility and specificity by separating eight different proteins, followed by an 18-month Phase 2 focused on increasing throughput and volume, demonstrated on two additional proteins that are difficult to purify using current state-of-the-art methods. To support this effort, DARPA is hosting an in-person Proposers Day on November 17, 2026, from 9:00 a.m. to 4:00 p.m. ET at the Executive Conference Center in Arlington, Virginia. Interested parties must register by November 9, 2026, and provide government-issued photo identification for entry. While the current Special Notice DARPA-SN-27-01 is for information and planning purposes and does not constitute a formal solicitation, DARPA anticipates releasing the full solicitation on sam.gov prior to the event. The Proposers Day will be held at the unclassified level, and any presented materials must be suitable for unlimited public release.
Defense Advanced Research Projects Agcy

POSTED

about 14 hours ago

DEADLINE

in 17 days
NAICS: 541715
New
Federal
Federal Aviation Administration (FAA) Research And Commercial Solutions Opening (RCSO) Area Of Interest (AOI) - Complexity Of Systems And Operations
Solicitation # 693KA8-27-T-00003
Solicitation 693KA8-27-T-00003 is a request from the Federal Aviation Administration for innovative research and solutions regarding the Complexity of Systems and Operations. This effort falls under the broader Research and Commercial Solutions Opening BAA-693KA8-26-RCSO and focuses on aviation safety research to advance the understanding of human factors and performance. Specifically, the agency is seeking solutions that address complexity from the perspectives of pilots and aircraft maintenance personnel, covering areas such as pilot-machine interfaces, the explainability of complex automation and artificial intelligence, and the mental models used for monitoring and troubleshooting complex systems. The goal is to produce high-quality human factors data, rigorously documented analyses, and actionable tools or criteria to enhance the National Airspace System. The procurement process is phased, beginning with the submission of Research/Solution Briefs, followed by Pitch Sessions, and concluding with a Request for Proposal for selected entities. Submissions are evaluated based on technical merit, innovation, relevance to the problem statement, and feasibility. Successful candidates will be awarded Other Transaction Agreements (OTAs), with terms and conditions negotiated directly between the Agreements Officer and the selected entity. All submissions must be unclassified, and the agency encourages participation from nontraditional government contractors, including small businesses. The response deadline for this specific Area of Interest is November 2, 2026.
693KA8 System Operations Contracts

POSTED

about 14 hours ago

DEADLINE

in 10 days

General Info

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Place of Performance

DC, USA

Set-Aside

NONE

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseClosed
Posted

special-notice

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → Advanced Research Projects Agency For Health (arpa-H)
Contacts1 person available
OfficeWashington, DC, 20005, USA

Full Description

Show more
The Advanced Research Projects Agency for Health (ARPA-H) is hosting a hybrid Proposers Day in support of a planned solicitation for the ACTR Initiative. Registration, date, time, and additional information can be found at: https://www.customerexperiencehub.org/advancing-clinical-trial-readiness-actr/

More opportunities from Department Of Health And Human Services → Advanced Research Projects Agency For Health (arpa-H)

Same awarding agency

NAICS: 541714
New
Federal
ARPA-H Emerging Health Innovators (EHI) Initiative
Solicitation # ARPA-H-SOL-26-150
The Advanced Research Projects Agency for Health (ARPA-H) Emerging Health Innovators (EHI) initiative, solicitation ARPA-H-SOL-26-150, seeks to identify and engage early-career investigators to develop cutting-edge biomedical, health, and community-engaged research. This opportunity is open to researchers from academic, nonprofit, and industry organizations, provided the Principal Investigator is within eight years of completing their first terminal degree. The initiative covers 16 specific topic areas, including AI in life sciences, brain stimulation, and human tissue platforms. Awards are issued as Other Transaction (OT) agreements, which are not subject to the Federal Acquisition Regulation (FAR). The selection process is a two-step submission involving an initial anonymized Solution Summary and a subsequent Full Proposal for selected candidates. Successful awards have a total value not to exceed 1,050,000 dollars over a three-year period, consisting of a 24-month base period capped at 700,000 dollars and an optional 12-month Director's Award period capped at 350,000 dollars. Payments are structured as fixed payments triggered by the completion of 12 discrete, measurable milestones. Full proposals are evaluated based on technical merit, innovativeness, feasibility, alignment with the ARPA-H mission to accelerate health outcomes, and price reasonableness. Administrative requirements include mandatory registration in SAM.gov and the use of the ARPA-H Solutions site for all submissions. Proposers must adhere to strict formatting templates for technical and management proposals, milestone schedules, and national policy requirements, including disclosures regarding organizational conflicts of interest and research security. Performance is monitored through a formal inspection and acceptance process where the government reviews deliverables within 14 calendar days. The tentative award start date is June 30, 2027, with full proposals due by February 10, 2027.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

1 day ago

DEADLINE

in 4 months
View Details
NAICS: 541715
New
Federal
Fast Assessment of Solutions, Therapeutics, Pharmaceuticals, and SupplieS (FASTPASS) Innovative Solutions Opening
Solicitation # ARPA-H-SOL-26-160
The Fast Assessment of Solutions, Therapeutics, Pharmaceuticals, and Supplies (FASTPASS) program, under solicitation ARPA-H-SOL-26-160, is an initiative by the Advanced Research Projects Agency for Health (ARPA-H) to develop a near real-time, non-destructive, AI-enabled screening system. The goal is to identify contamination, adulteration, and quality defects in pharmaceutical products through their packaging at ports of entry and other supply-chain nodes using multi-modal sensing and data fusion. This 54-month program is structured into three 18-month phases, culminating in a fieldable platform with validated training materials and integrated documentation capabilities. This procurement is conducted as a multiple-award Other Transaction (OT) Agreement rather than a standard federal contract, meaning it is governed by specific OT articles instead of the Federal Acquisition Regulation. Awards are based on the most advantageous proposals, with primary evaluation factors including innovation, soundness, execution planning, risk management, and team expertise. Payments are fixed and triggered by the successful completion of milestones, managed through the Payment Management System. Proposers must be registered in SAM.gov and provide detailed technical and cost proposals, including a milestone payment schedule and research security disclosures. Amendment 01 specifically updated the cost proposal narrative model and workbook to correct typographical errors and rename appendices.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

3 days ago

DEADLINE

in 18 days
View Details
NAICS: 541714
Federal
Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS)
Solicitation # ARPA-H-SOL-26-164
The Advanced Research Projects Agency for Health (ARPA-H) is soliciting proposals for the Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) program under solicitation ARPA-H-SOL-26-164. This five-year initiative aims to create a reusable blueprint for future adaptive seamless platform trials through the integration of three technical areas: a Phaseless Design Engine, Continuous Inference, and Agentic Operations. The program is divided into two stages, with Stage I focusing on capability buildout, FDA engagement, and the onboarding of at least three intervention arms over 24 months, followed by a 36-month Stage II dedicated to validation and deployment. A critical go/no-go milestone is obtaining FDA authorization for the platform Master Protocol IND and at least one investigational arm by the end of Stage I. The government intends to make multiple awards via Other Transaction Agreements to proposers offering the most advantageous solutions based on innovation, feasibility, and technical merit at reasonable prices. Eligible entities must possess a Unique Entity Identifier and active SAM registration. Proposals are submitted in a phased approach, beginning with a Solution Summary and potentially progressing to a Solution Pitch package. Performance will be measured by the successful integration of the three technical areas and the achievement of specific program metrics. All work must adhere to ICH E6(R3) Good Clinical Practice and strict regulatory standards to ensure inspection readiness and participant safety.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

24 days ago

DEADLINE

in about 1 month
View Details
NAICS: 541714
Federal
UNifying Imaging with QUantum Entanglement (UNIQUE) Innovative Solutions Opening (ISO)
Solicitation # ARPA-H-SOL-26-162
The Advanced Research Projects Agency for Health (ARPA-H) is seeking innovative solutions through the UNifying Imaging with QUantum Entanglement (UNIQUE) program, solicitation number ARPA-H-SOL-26-162. This 18-month, two-phase initiative aims to develop a new biomedical imaging paradigm by integrating anatomical, functional, and molecular data using quantum-derived observables and entangled 511 keV photon pairs. The scope is divided into two technical areas: the Imaging Core, which focuses on physical systems for generating and measuring quantum observables, and the Computational Foundation, which focuses on AI-driven reconstruction and multimodal data fusion. ARPA-H anticipates awarding multiple Other Transaction Agreements to eligible universities, non-profit organizations, and businesses. The submission process is two-staged, requiring Solution Summaries by late October 2026 and Full Proposals by December 15, 2026. Full proposals must consist of three volumes covering technical and management plans, cost proposals, and administrative requirements. Evaluation is based on technical innovation and feasibility, proposer expertise, potential to transform biomedicine, and cost reasonableness. Notably, for-profit organizations that are not small businesses under NAICS 541714 are required to provide a meaningful cost share. All participants must adhere to strict HHS regulations regarding human stem cell research and prohibitions on dangerous gain-of-function research and funding for foreign entities in countries of concern.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

30 days ago

DEADLINE

in about 2 months
View Details

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS